{"title":"拉斯米坦:第一种神经作用的抗偏头痛药物","authors":"S. Bhanwra, S. Mahajan, R. Kumar","doi":"10.18203/2319-2003.IJBCP20212088","DOIUrl":null,"url":null,"abstract":"Lasmiditan is the first neurally acting drug for the treatment of acute migraine. It is a highly selective, orally acting 5HT1F agonist that was approved in November 2019, for the acute treatment of migraine in adults, with or without aura, by USFDA. Lesmiditan may help in terminating the acute attack of migraine by inhibiting the central and peripheral neuronal activity and the release of CGRP.","PeriodicalId":13898,"journal":{"name":"International journal of basic and clinical pharmacology","volume":"41 1","pages":"745"},"PeriodicalIF":0.0000,"publicationDate":"2021-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Lasmiditan: the first neurally acting anti-migraine drug\",\"authors\":\"S. Bhanwra, S. Mahajan, R. Kumar\",\"doi\":\"10.18203/2319-2003.IJBCP20212088\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Lasmiditan is the first neurally acting drug for the treatment of acute migraine. It is a highly selective, orally acting 5HT1F agonist that was approved in November 2019, for the acute treatment of migraine in adults, with or without aura, by USFDA. Lesmiditan may help in terminating the acute attack of migraine by inhibiting the central and peripheral neuronal activity and the release of CGRP.\",\"PeriodicalId\":13898,\"journal\":{\"name\":\"International journal of basic and clinical pharmacology\",\"volume\":\"41 1\",\"pages\":\"745\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-05-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International journal of basic and clinical pharmacology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18203/2319-2003.IJBCP20212088\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of basic and clinical pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18203/2319-2003.IJBCP20212088","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Lasmiditan: the first neurally acting anti-migraine drug
Lasmiditan is the first neurally acting drug for the treatment of acute migraine. It is a highly selective, orally acting 5HT1F agonist that was approved in November 2019, for the acute treatment of migraine in adults, with or without aura, by USFDA. Lesmiditan may help in terminating the acute attack of migraine by inhibiting the central and peripheral neuronal activity and the release of CGRP.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
